Literature DB >> 10980389

IgE production after antigen-specific and cognate activation of HLA-DPw4-restricted T-cell clones, by 78% of randomly selected B-cell donors.

P J Baselmans1, E Pöllabauer, F C van Reijsen, H C Heystek, A Hren, P Stumptner, M G Tilanus, W C Vooijs, G C Mudde.   

Abstract

The frequency of expression of the MHC class II antigen, HLA-DPw4, in the caucasoid population is approximately 78%, and is unmatched by phenotypic frequencies of other HLA class II molecules. Here we describe three human Der-P1-specific T-cell clones (TCC), restricted by the HLA-DPw4-variant HLA-DPB1*0401, of which two TCC also responded to antigen, presented on HLA-DPB1*0402. Thus, randomly selected caucasoid donors present a 78% chance for a correct match with these HLA-DPw4-restricted TCC. This allows comparative in vitro antigen presentation studies with various antigen presenting cells (APC) from different (healthy or diseased) donors without the variable influence of responding T cells. It was subsequently demonstrated that the TCC can be used to study antigen-induced IgE production in randomly selected primary B cells. Cognate HLA-DPw4-restricted antigen presentation caused enhanced immunoglobulin production of IgE, IgG1, IgA and IgM, of which only IgE induction was reversed by addition of anti-IL-4 antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980389     DOI: 10.1016/s0198-8859(00)00137-3

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  EWI-2/CD316 is an inducible receptor of HSPA8 on human dendritic cells.

Authors:  Sandra Kettner; Frank Kalthoff; Philipp Graf; Elisabeth Priller; Franz Kricek; Ivan Lindley; Tamás Schweighoffer
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

2.  Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.

Authors:  L de Waal; S Yüksel; A H Brandenburg; J P M Langedijk; K Sintnicolaas; G M G M Verjans; A D M E Osterhaus; R L de Swart
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.